{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:10:24Z","timestamp":1707937824662},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1999,6,1]],"date-time":"1999-06-01T00:00:00Z","timestamp":928195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[1999,6]]},"DOI":"10.1007\/s11926-999-0023-3","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T13:04:44Z","timestamp":1180789484000},"page":"38-42","source":"Crossref","is-referenced-by-count":0,"title":["Penicillamine in the treatment of systemic sclerosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Philip J.","family":"Clements","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0140-6736(66)92926-6","volume":"2","author":"ED Harris","year":"1966","unstructured":"Harris ED, Sjoerdsma A: Effect of penicillamine on human collagen and possible application to treatment of scleroderma. Lancet 1966, 2:996\u2013999.","journal-title":"Lancet"},{"key":"23_CR2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archderm.1968.01610130057012","volume":"98","author":"DD Fulghum","year":"1968","unstructured":"Fulghum DD, Katz R: Penicillamine for scleroderma. Arch Dermatol 1968, 98:51\u201352.","journal-title":"Arch Dermatol"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.29.2.153","volume":"29","author":"R Bluestone","year":"1970","unstructured":"Bluestone R, Grahame R, Holloway V, Holt PJ: Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment. Ann Rheum Dis 1970, 29:153\u2013158.","journal-title":"Ann Rheum Dis"},{"key":"23_CR4","first-page":"128","volume":"46","author":"RK Winkelmann","year":"1971","unstructured":"Winkelmann RK, Kierland RR, Perry HD: Management of scleroderma. Mayo Clin Proc 1971, 46:128\u2013134.","journal-title":"Mayo Clin Proc"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/03009747209103010","volume":"1","author":"IB Lorenzen","year":"1972","unstructured":"Lorenzen IB, Uitto J, Ohlenschlaeger K: D-DPA in progressive scleroderma. Scand J Rheumatol 1972, 1:121\u2013124.","journal-title":"Scand J Rheumatol"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.0954-6820.1973.tb10612.x","volume":"193","author":"H Tio","year":"1973","unstructured":"Tio H, van Wikk L, Haan E: Treatment of progressive systemic sclerosis (PSS) with penicillamine. Preliminary report of two cases. Acta Med Scand 1973, 193:477\u2013480.","journal-title":"Acta Med Scand"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(74)92494-5","volume":"1","author":"CM Herbert","year":"1974","unstructured":"Herbert CM, Lindberg KA, Jayson MI, Bailey AJ: Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974, 1:187\u2013192.","journal-title":"Lancet"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2340\/000155555461465","volume":"55","author":"G Asboe-Hansen","year":"1975","unstructured":"Asboe-Hansen G: Treatment of generalized scleroderma with inhibitors of connective tissue formation. Acta Derm Venereol (Stockh) 1975, 55:461\u2013465.","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"23_CR9","first-page":"290","volume-title":"Penicillamine Research in Rheumatoid Disease","author":"H Zachariae","year":"1976","unstructured":"Zachariae H, Petersen HO, Zachariae E: D-penicillamine in scleroderma: a preliminary study. In Penicillamine Research in Rheumatoid Disease. Edited by Munthe E. Oslo, Norway: Fabritius and Sonner; 1976: 290."},{"key":"23_CR10","first-page":"82","volume":"70","author":"MIV Jayson","year":"1977","unstructured":"Jayson MIV, Lovell C, Black CM, Wilson RS: Penicillamine therapy in systemic sclerosis. Proc R Soc Med 1977, 70:82\u201388.","journal-title":"Proc R Soc Med"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/03009747709095427","volume":"6","author":"H Mellstedt","year":"1977","unstructured":"Mellstedt H, Fagrell B, Bjokholm M: Effect on nutritional capillary circulation. Scand J Rheumatol 1977, 6:92\u201396.","journal-title":"Scand J Rheumatol"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7326\/0003-4819-97-5-652","volume":"97","author":"VD Steen","year":"1982","unstructured":"Steen VD, Medsger TA, Jr, Rodnan GP: D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982, 97:652\u2013659.","journal-title":"Ann Intern Med"},{"key":"23_CR13","first-page":"1496","volume":"18","author":"SA Jimenez","year":"1991","unstructured":"Jimenez SA, Sigal SH: A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheum 1991, 18:1496\u20131503.","journal-title":"J Rheum"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-104-5-699","volume":"104","author":"VD Steen","year":"1986","unstructured":"Steen VD, Blair S, Medsger TA Jr.: The toxicity of D-DPA in systemic sclerosis. Ann Intern Med 1986, 104:699\u2013705. Seminal study which propelled the interest in using D-penicillamine in systemic sclerosis. It provided preliminary data for design of a randomized controlled trial - the High-Dose vs Low-Dose Penicillamine in Early Diffuse Systemic Sclerosis Trial.","journal-title":"Ann Intern Med"},{"key":"23_CR15","first-page":"S173","volume":"40","author":"PJ Clements","year":"1997","unstructured":"Clements PJ, Wong WK, Seibold JR, et al.: High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of trial. Arthritis Rheum. 1997, 40:S173. Both references provide the results of the analysis of the High-Dose vs Low-Dose Penicillamine in Early Diffuse Systemic Sclerosis Trial, which showed that the skin scores in both groups improved to the same degree and that there were no significant differences in the occurrence of renal crisis or death between the two treatment groups.","journal-title":"Arthritis Rheum."},{"key":"23_CR16","unstructured":"Clements PJ, Wong WK, Seibold JR, et al.: High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of trial. Arthritis Rheum, in press. Both references provide the results of the analysis of the High-Dose vs Low-Dose Penicillamine in Early Diffuse Systemic Sclerosis Trial, which showed that the skin scores in both groups improved to the same degree and that there were no significant differences in the occurrence of renal crisis or death between the two treatment groups."},{"key":"23_CR17","first-page":"51","volume-title":"Systemic Sclerosis","author":"TA Medsger Jr","year":"1996","unstructured":"Medsger TA, Jr, Steen VD: Classification, prognosis. In Systemic Sclerosis. Edited by Clements PJ, Furst DE. Baltimore: Williams and Wilkins; 1996: 51\u201364."},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780380309","volume":"38","author":"B White","year":"1995","unstructured":"White B, Bauer EA, Goldsmith LA, et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Diseasemodifying interventions. Arthritis Rheum 1995, 38:351\u2013360.","journal-title":"Arthritis Rheum"},{"key":"23_CR19","first-page":"441","volume":"8","author":"GA Colditz","year":"1989","unstructured":"Colditz GA, Miller JN, Mosteller F: How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989, 8:441\u2013444.","journal-title":"I: Medical. Stat Med"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al.: Assessing the quality of report of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1\u201312.","journal-title":"Control Clin Trials"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-999-0023-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-999-0023-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-999-0023-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T18:54:53Z","timestamp":1707936893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-999-0023-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11926-999-0023-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}